Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2024

Open Access 01-12-2024 | Review

Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases

Authors: Dillon J. Rinauro, Fabrizio Chiti, Michele Vendruscolo, Ryan Limbocker

Published in: Molecular Neurodegeneration | Issue 1/2024

Login to get access

Abstract

The conversion of native peptides and proteins into amyloid aggregates is a hallmark of over 50 human disorders, including Alzheimer’s and Parkinson’s diseases. Increasing evidence implicates misfolded protein oligomers produced during the amyloid formation process as the primary cytotoxic agents in many of these devastating conditions. In this review, we analyze the processes by which oligomers are formed, their structures, physicochemical properties, population dynamics, and the mechanisms of their cytotoxicity. We then focus on drug discovery strategies that target the formation of oligomers and their ability to disrupt cell physiology and trigger degenerative processes.
Literature
1.
Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem. 2017;86:27–68.PubMedCrossRef
2.
Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol. 2014;15:384–96.PubMedCrossRef
3.
4.
5.
Yang Y, Arseni D, Zhang W, Huang M, Lövestam S, Schweighauser M, et al. Cryo-EM structures of amyloid-β 42 filaments from human brains. Science. 2022;375:167–72.ADSPubMedPubMedCentralCrossRef
6.
Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022;29:213–9.PubMedCrossRef
7.
8.
Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci. 1986;83:4040–3.
9.
Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084–9.
10.
Hardy JA, Higgins GA. Alzheimer’s Disease: The amyloid cascade hypothesis. Science. 1992;256:184–5.
11.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci. 1985;82:4245–9.
12.
Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388:839–40.
13.
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95:6469–73.
14.
Palato LM, Pilcher S, Oakes A, Lamba A, Torres J, Ledesma Monjaraz LI, et al. Amyloidogenicity of naturally occurring fulllength animal IAPP variants. J Pept Sci. 2019;25:e3199.
15.
Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986;140:827–31.
16.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.PubMedCrossRef
17.
Sengupta U, Nilson AN, Kayed R. The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. eBioMedicine. 2016;6:42–9.
18.
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener. 2011;6:39.PubMedPubMedCentralCrossRef
19.
Du F, Yu Q, Kanaan NM, Yan SS. Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of tau oligomers in Alzheimer’s disease. Hum Mol Genet. 2022;31:2498–507.PubMedPubMedCentralCrossRef
20.
21.
Cohen SIA, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci USA. 2013;110:9758–63.ADSPubMedPubMedCentralCrossRef
22.
Meisl G, Yang X, Hellstrand E, Frohm B, Kirkegaard JB, Cohen SIA, et al. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Proc Natl Acad Sci USA. 2014;111:9384–9.ADSPubMedPubMedCentralCrossRef
23.
Rodriguez Camargo DC, Sileikis E, Chia S, Axell E, Bernfur K, Cataldi RL, et al. Proliferation of Tau 304–380 fragment aggregates through autocatalytic secondary nucleation. ACS Chem Neurosci. 2021;12:4406–15.PubMedCrossRef
24.
Sachse C, Fändrich M, Grigorieff N. Paired β-sheet structure of an Aβ(1–40) amyloid fibril revealed by electron microscopy. Proc Natl Acad Sci USA. 2008;105:7462–6.ADSPubMedPubMedCentralCrossRef
25.
Gremer L, Schölzel D, Schenk C, Reinartz E, Labahn J, Ravelli RBG, et al. Fibril structure of amyloid-β(1–42) by cryo–electron microscopy. Science. 2017;358:116–9.ADSPubMedPubMedCentralCrossRef
26.
Lövestam S, Koh FA, van Knippenberg B, Kotecha A, Murzin AG, Goedert M, et al. Assembly of recombinant tau into filaments identical to those of Alzheimer’s disease and chronic traumatic encephalopathy. eLife. 2022;11:e76494.
27.
Ghosh U, Thurber KR, Yau W-M, Tycko R. Molecular structure of a prevalent amyloid-β fibril polymorph from Alzheimer’s disease brain tissue. Proc Natl Acad Sci USA. 2021;118: e2023089118.PubMedPubMedCentralCrossRef
28.
Kollmer M, Close W, Funk L, Rasmussen J, Bsoul A, Schierhorn A, et al. Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer’s brain tissue. Nat Commun. 2019;10:4760.ADSPubMedPubMedCentralCrossRef
29.
Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547:185–90.ADSPubMedPubMedCentralCrossRef
30.
Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. Acta Neuropathol (Berl). 2018;136:699–708.PubMedCrossRef
31.
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108:4194–9.ADSPubMedPubMedCentralCrossRef
32.
Emin D, Zhang YP, Lobanova E, Miller A, Li X, Xia Z, et al. Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease. Nat Commun. 2022;13:5512.ADSPubMedPubMedCentralCrossRef
33.
Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, et al. Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science. 2017;358:1440–3.ADSPubMedCrossRef
34.
Horne RI, Metrick MAI, Man W, Rinauro DJ, Brotzakis ZF, Chia S, et al. Secondary processes dominate the quiescent, spontaneous aggregation of α-synuclein at physiological pH with sodium salts. ACS Chem Neurosci. 2023;14:3125–31.
35.
Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TPJ, et al. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc Natl Acad Sci USA. 2014;111:7671–6.ADSPubMedPubMedCentralCrossRef
36.
37.
Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, et al. Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy. Cell Res. 2018;28:897–903.PubMedPubMedCentralCrossRef
38.
Boyer DR, Li B, Sun C, Fan W, Sawaya MR, Jiang L, et al. Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs. Nat Struct Mol Biol. 2019;26:1044–52.PubMedPubMedCentralCrossRef
39.
Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, et al. Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol. 2016;23:409–15.PubMedPubMedCentralCrossRef
40.
Yang Y, Shi Y, Schweighauser M, Zhang X, Kotecha A, Murzin AG, et al. Structures of α-synuclein filaments from human brains with Lewy pathology. Nature. 2022;610:791–5.ADSPubMedCrossRef
41.
42.
Strohäker T, Jung BC, Liou S-H, Fernandez CO, Riedel D, Becker S, et al. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nat Commun. 2019;10:5535.ADSPubMedPubMedCentralCrossRef
43.
Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27:1405–10.PubMedPubMedCentralCrossRef
44.
Paleologou KE, Kragh CL, Mann DMA, Salem SA, Al-Shami R, Allsop D, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain J Neurol. 2009;132:1093–101.CrossRef
45.
46.
Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, Cagnin A, et al. α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol. 2019;6:2120–6.PubMedPubMedCentralCrossRef
47.
48.
Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther. 2014;6:25.PubMedPubMedCentralCrossRef
49.
Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP. Annular α-synuclein species from purified multiple system atrophy inclusions. J Neurochem. 2004;90:502–12.PubMedCrossRef
50.
Cascella R, Bigi A, Cremades N, Cecchi C. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cell Mol Life Sci. 2022;79:174.PubMedPubMedCentralCrossRef
51.
Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature. 2020;585:464–9.ADSPubMedPubMedCentralCrossRef
52.
Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16:529–46.PubMedCrossRef
53.
Wetzel R. Exploding the repeat length paradigm while exploring amyloid toxicity in Huntington’s disease. Acc Chem Res. 2020;53:2347–57.PubMedCrossRef
54.
Gropp MHM, Klaips CL, Hartl FU. Formation of toxic oligomers of polyQ-expanded Huntingtin by prion-mediated cross-seeding. Mol Cell. 2022;82:4290–4306.e11.PubMedCrossRef
55.
Sinnige T, Meisl G, Michaels TCT, Vendruscolo M, Knowles TPJ, Morimoto RI. Kinetic analysis reveals that independent nucleation events determine the progression of polyglutamine aggregation in C. elegans. Proc Natl Acad Sci USA. 2021;118:e2021888118.
56.
Nazarov S, Chiki A, Boudeffa D, Lashuel HA. Structural basis of Huntingtin fibril polymorphism revealed by cryogenic electron microscopy of exon 1 HTT fibrils. J Am Chem Soc. 2022;144:10723–35.PubMedCrossRef
57.
58.
Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420–3.ADSPubMedPubMedCentralCrossRef
59.
Metrick MA, Ferreira N do C, Saijo E, Kraus A, Newell K, Zanusso G, et al. A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathol Commun. 2020;8:22.
60.
Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature. 2018;561:137.ADSPubMedPubMedCentralCrossRef
61.
Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol (Berl). 2020;139:63–77.PubMedCrossRef
62.
63.
Woerman AL, Aoyagi A, Patel S, Kazmi SA, Lobach I, Grinberg LT, et al. Tau prions from Alzheimer’s disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc Natl Acad Sci USA. 2016;113:E8187–96.PubMedPubMedCentralCrossRef
64.
Chung DC, Carlomagno Y, Cook CN, Jansen-West K, Daughrity L, Lewis-Tuffin LJ, et al. Tau exhibits unique seeding properties in globular glial tauopathy. Acta Neuropathol Commun. 2019;7:36.PubMedPubMedCentralCrossRef
65.
66.
Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids and pathological membrane interactions. Annu Rev Biochem. 2009;78:177–204.PubMedPubMedCentralCrossRef
67.
Sigurdson CJ, Bartz JC, Glatzel M. Cellular and molecular mechanisms of prion disease. Annu Rev Pathol. 2019;14:497–516.PubMedCrossRef
68.
Meisl G, Kurt T, Condado-Morales I, Bett C, Sorce S, Nuvolone M, et al. Scaling analysis reveals the mechanism and rates of prion replication in vivo. Nat Struct Mol Biol. 2021;28:365–72.PubMedPubMedCentralCrossRef
69.
Wang L-Q, Zhao K, Yuan H-Y, Li X-N, Dang H-B, Ma Y, et al. Genetic prion disease–related mutation E196K displays a novel amyloid fibril structure revealed by cryo-EM. Sci Adv. 2021;7:eabg9676.
70.
Kraus A, Hoyt F, Schwartz CL, Hansen B, Artikis E, Hughson AG, et al. High-resolution structure and strain comparison of infectious mammalian prions. Mol Cell. 2021;81:4540–4551.e6.PubMedCrossRef
71.
Wang L-Q, Zhao K, Yuan H-Y, Wang Q, Guan Z, Tao J, et al. Cryo-EM structure of an amyloid fibril formed by full-length human prion protein. Nat Struct Mol Biol. 2020;27:598–602.PubMedCrossRef
72.
Glynn C, Sawaya MR, Ge P, Gallagher-Jones M, Short CW, Bowman R, et al. Cryo-EM structure of a human prion fibril with a hydrophobic, protease-resistant core. Nat Struct Mol Biol. 2020;27:417–23.PubMedPubMedCentralCrossRef
73.
74.
Manka SW, Zhang W, Wenborn A, Betts J, Joiner S, Saibil HR, et al. 2.7 Å cryo-EM structure of ex vivo RML prion fibrils. Nat Commun. 2022;13:4004.
75.
Hoyt F, Standke HG, Artikis E, Schwartz CL, Hansen B, Li K, et al. Cryo-EM structure of anchorless RML prion reveals variations in shared motifs between distinct strains. Nat Commun. 2022;13:4005.ADSPubMedPubMedCentralCrossRef
76.
Kamali-Jamil R, Vázquez-Fernández E, Tancowny B, Rathod V, Amidian S, Wang X, et al. The ultrastructure of infectious L-type bovine spongiform encephalopathy prions constrains molecular models. PLOS Pathog. 2021;17:e1009628.
77.
Bram Y, Frydman-Marom A, Yanai I, Gilead S, Shaltiel-Karyo R, Amdursky N, et al. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies. Sci Rep. 2014;4:4267.ADSPubMedPubMedCentralCrossRef
78.
Gurlo T, Ryazantsev S, Huang C, Yeh MW, Reber HA, Hines OJ, et al. Evidence for proteotoxicity in β cells in Type 2 Diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol. 2010;176:861–9.PubMedPubMedCentralCrossRef
79.
80.
Gallardo R, Iadanza MG, Xu Y, Heath GR, Foster R, Radford SE, et al. Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly. Nat Struct Mol Biol. 2020;27:1048–56.PubMedCrossRef
81.
Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS. Cryo-EM structure and inhibitor design of human IAPP (amylin) fibrils. Nat Struct Mol Biol. 2020;27:653–9.PubMedPubMedCentralCrossRef
82.
Cao Q, Boyer DR, Sawaya MR, Abskharon R, Saelices L, Nguyen BA, et al. Cryo-EM structures of hIAPP fibrils seeded by patient-extracted fibrils reveal new polymorphs and conserved fibril cores. Nat Struct Mol Biol. 2021;28:724–30.PubMedPubMedCentralCrossRef
83.
Meehan S, Berry Y, Luisi B, Dobson CM, Carver JA, MacPhee CE. Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. J Biol Chem. 2004;279:3413–9.PubMedCrossRef
84.
85.
Bansal A, Schmidt M, Rennegarbe M, Haupt C, Liberta F, Stecher S, et al. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils. Nat Commun. 2021;12:1013.ADSPubMedPubMedCentralCrossRef
86.
Jayaraman S, Gantz DL, Haupt C, Gursky O. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. Proc Natl Acad Sci USA. 2017;114:E6507–15.ADSPubMedPubMedCentralCrossRef
87.
Westermark GT, Westermark P. Serum amyloid A and protein AA: Molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 2009;583:2685–90.PubMedCrossRef
88.
Heerde T, Rennegarbe M, Biedermann A, Savran D, Pfeiffer PB, Hitzenberger M, et al. Cryo-EM demonstrates the in vitro proliferation of an ex vivo amyloid fibril morphology by seeding. Nat Commun. 2022;13:85.ADSPubMedPubMedCentralCrossRef
89.
Teixeira PF, Cerca F, Santos SD, Saraiva MJ. Endoplasmic reticulum stress associated with extracellular aggregates: evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem. 2006;281:21998–2003.PubMedCrossRef
90.
Andersson K, Olofsson A, Nielsen EH, Svehag S-E, Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun. 2002;294:309–14.PubMedCrossRef
91.
Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA. 2004;101:2817–22.ADSPubMedPubMedCentralCrossRef
92.
Steinebrei M, Gottwald J, Baur J, Röcken C, Hegenbart U, Schönland S, et al. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis. Nat Commun. 2022;13:6398.ADSPubMedPubMedCentralCrossRef
93.
Schmidt M, Wiese S, Adak V, Engler J, Agarwal S, Fritz G, et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat Commun. 2019;10:5008.ADSPubMedPubMedCentralCrossRef
94.
Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primer. 2018;4:1–19.CrossRef
95.
Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 2017;7:15661.
96.
Blancas-Mejía LM, Ramirez-Alvarado M. Recruitment of light chains by homologous and heterologous fibrils shows distinctive kinetic and conformational specificity. Biochemistry. 2016;55:2967–78.PubMedCrossRef
97.
Radamaker L, Baur J, Huhn S, Haupt C, Hegenbart U, Schönland S, et al. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. Nat Commun. 2021;12:875.ADSPubMedPubMedCentralCrossRef
98.
Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, et al. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nat Commun. 2019;10:1269.ADSPubMedPubMedCentralCrossRef
99.
Dasari AKR, Yi S, Coats MF, Wi S, Lim KH. Toxic Misfolded transthyretin oligomers with different molecular conformations formed through distinct oligomerization pathways. Biochemistry. 2022;61:2358–65.PubMedCrossRef
100.
Bemporad F, Chiti F. Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships. Chem Biol. 2012;19:315–27.PubMedCrossRef
101.
Kreiser RP, Wright AK, Block NR, Hollows JE, Nguyen LT, LeForte K, et al. Therapeutic strategies to reduce the toxicity of misfolded protein oligomers. Int J Mol Sci. 2020;21:8651.PubMedPubMedCentralCrossRef
102.
Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol. 2007;8:101–12.PubMedCrossRef
103.
Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349–57.PubMedCrossRef
104.
105.
106.
Pieri L, Madiona K, Bousset L, Melki R. Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys J. 2012;102:2894–905.PubMedPubMedCentralCrossRef
107.
Scheidt T, Łapińska U, Kumita JR, Whiten DR, Klenerman D, Wilson MR, et al. Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates. Sci Adv. 2019;5:eaau3112.
108.
Cascella R, Chen SW, Bigi A, Camino JD, Xu CK, Dobson CM, et al. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nat Commun. 2021;12:1814.ADSPubMedPubMedCentralCrossRef
109.
Josephs KA, Ahlskog JE, Parisi JE, Boeve BF, Crum BA, Giannini C, et al. Rapidly progressive neurodegenerative dementias. Arch Neurol. 2009;66:201–7.PubMedPubMedCentralCrossRef
110.
Rösler TW, Tayaranian Marvian A, Brendel M, Nykänen N-P, Höllerhage M, Schwarz SC, et al. Four-repeat tauopathies. Prog Neurobiol. 2019;180: 101644.PubMedCrossRef
111.
Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14:626–36.
112.
113.
Chia S, Habchi J, Michaels TCT, Cohen SIA, Linse S, Dobson CM, et al. SAR by kinetics for drug discovery in protein misfolding diseases. Proc Natl Acad Sci USA. 2018;115:10245–50.ADSPubMedPubMedCentralCrossRef
114.
Michaels TCT, Dear AJ, Cohen SIA, Vendruscolo M, Knowles TPJ. Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers. J Chem Phys. 2022;156: 164904.PubMedCrossRef
115.
116.
Limbocker R, Cremades N, Cascella R, Tessier PM, Vendruscolo M, Chiti F. Characterization of pairs of toxic and nontoxic misfolded protein oligomers elucidates the structural determinants of oligomer toxicity in protein misfolding diseases. Acc Chem Res. 2023;56:1395–405.PubMedPubMedCentralCrossRef
117.
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol. 1999;46:860–6.PubMedCrossRef
118.
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486–9.ADSPubMedCrossRef
119.
Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007;27:796–807.PubMedPubMedCentralCrossRef
120.
Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.PubMedPubMedCentralCrossRef
121.
Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, et al. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem. 2009;284:32895–905.PubMedPubMedCentralCrossRef
122.
Hillen H, Barghorn S, Striebinger A, Labkovsky B, Müller R, Nimmrich V, et al. Generation and therapeutic efficacy of highly oligomer-specific β-amyloid antibodies. J Neurosci. 2010;30:10369–79.PubMedPubMedCentralCrossRef
123.
Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, et al. Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer’s disease. PLoS ONE. 2013;8: e66381.ADSPubMedPubMedCentralCrossRef
124.
Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, et al. A sensitive aβ oligomer assay discriminates Alzheimer’s and aged control cerebrospinal fluid. J Neurosci. 2014;34:2884–97.PubMedPubMedCentralCrossRef
125.
Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, et al. Tau oligomers in cerebrospinal fluid in Alzheimer’s disease. Ann Clin Transl Neurol. 2017;4:226–35.PubMedPubMedCentralCrossRef
126.
Vecchi G, Sormanni P, Mannini B, Vandelli A, Tartaglia GG, Dobson CM, et al. Proteome-wide observation of the phenomenon of life on the edge of solubility. Proc Natl Acad Sci USA. 2020;117:1015–20.ADSPubMedCrossRef
127.
Tartaglia GG, Pechmann S, Dobson CM, Vendruscolo M. Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem Sci. 2007;32:204–6.PubMedCrossRef
128.
Baldwin AJ, Knowles TPJ, Tartaglia GG, Fitzpatrick AW, Devlin GL, Shammas SL, et al. Metastability of native proteins and the phenomenon of amyloid formation. J Am Chem Soc. 2011;133:14160–3.PubMedCrossRef
129.
130.
Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729–39.PubMedCrossRef
131.
132.
Fuxreiter M, Vendruscolo M. Generic nature of the condensed states of proteins. Nat Cell Biol. 2021;23:587–94.PubMedCrossRef
133.
134.
135.
Scheres SH, Zhang W, Falcon B, Goedert M. Cryo-EM structures of tau filaments. Curr Opin Struct Biol. 2020;64:17–25.PubMedCrossRef
136.
Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601:139–43.ADSPubMedCrossRef
137.
Sawaya MR, Hughes MP, Rodriguez JA, Riek R, Eisenberg DS. The expanding amyloid family: Structure, stability, function, and pathogenesis. Cell. 2021;184:4857–73.PubMedPubMedCentralCrossRef
138.
Lu J-X, Qiang W, Yau W-M, Schwieters CD, Meredith SC, Tycko R. Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell. 2013;154:1257–68.PubMedCrossRef
139.
140.
Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324–32.PubMedCrossRef
141.
Knowles TP, Fitzpatrick AW, Meehan S, Mott HR, Vendruscolo M, Dobson CM, et al. Role of intermolecular forces in defining material properties of protein nanofibrils. Science. 2007;318:1900–3.ADSPubMedCrossRef
142.
Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid – from bacteria to humans. Trends Biochem Sci. 2007;32:217–24.PubMedCrossRef
143.
144.
Hervas R, Rau MJ, Park Y, Zhang W, Murzin AG, Fitzpatrick JAJ, et al. Cryo-EM structure of a neuronal functional amyloid implicated in memory persistence in Drosophila. Science. 2020;367:1230–4.ADSPubMedPubMedCentralCrossRef
145.
Meisl G, Xu CK, Taylor JD, Michaels TCT, Levin A, Otzen D, et al. Uncovering the universality of self-replication in protein aggregation and its link to disease. Sci Adv. 2022;8:eabn6831.
146.
Shimanovich U, Ruggeri FS, Genst ED, Adamcik J, Barros TP, Porter D, et al. Silk micrococoons for protein stabilisation and molecular encapsulation. Nat Commun. 2017;8:15902.ADSPubMedPubMedCentralCrossRef
147.
Bolisetty S, Mezzenga R. Amyloid–carbon hybrid membranes for universal water purification. Nat Nanotechnol. 2016;11:365–71.ADSPubMedCrossRef
148.
Horvath I, Wittung-Stafshede P. Amyloid fibers of α-synuclein catalyze chemical reactions. ACS Chem Neurosci. 2023;14:603–8.PubMedCrossRef
149.
Arad E, Baruch Leshem A, Rapaport H, Jelinek R. β-Amyloid fibrils catalyze neurotransmitter degradation. Chem Catal. 2021;1:908–22.CrossRef
150.
Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364–72.
151.
Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997;4:119–25.PubMedCrossRef
152.
Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564–70.PubMedCrossRef
153.
Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-β1-42 oligomers to fibrils. Nat Struct Mol Biol. 2010;17:561–7.PubMedPubMedCentralCrossRef
154.
Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y. Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer’s β-amyloid. Nat Struct Mol Biol. 2007;14:1157–64.PubMedCrossRef
155.
Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc Natl Acad Sci USA. 2003;100:6370–5.ADSPubMedPubMedCentralCrossRef
156.
Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem. 2005;95:834–47.PubMedCrossRef
157.
Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem. 2009;284:4230–7.PubMedPubMedCentralCrossRef
158.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448–53.ADSPubMedPubMedCentralCrossRef
159.
Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc Natl Acad Sci USA. 2003;100:330–5.ADSPubMedCrossRef
160.
Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell. 2012;149:1048–59.PubMedPubMedCentralCrossRef
161.
Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci USA. 2015;112:E1994–2003.PubMedPubMedCentral
162.
Gallea JI, Celej MS. Structural insights into amyloid oligomers of the Parkinson disease-related protein α-synuclein. J Biol Chem. 2014;289:26733–42.PubMedPubMedCentralCrossRef
163.
Lorenzen N, Nielsen SB, Buell AK, Kaspersen JD, Arosio P, Vad BS, et al. The role of stable α-Synuclein oligomers in the molecular events underlying amyloid formation. J Am Chem Soc. 2014;136:3859–68.PubMedCrossRef
164.
165.
Parthasarathy S, Inoue M, Xiao Y, Matsumura Y, Nabeshima Y, Hoshi M, et al. Structural insight into an alzheimer’s brain-derived spherical assembly of amyloid β by solid-state NMR. J Am Chem Soc. 2015;137:6480–3.PubMedPubMedCentralCrossRef
166.
O’Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Amyloid β-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411–9.PubMedPubMedCentralCrossRef
167.
Carulla N, Zhou M, Arimon M, Gairí M, Giralt E, Robinson CV, et al. Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation. Proc Natl Acad Sci USA. 2009;106:7828–33.ADSPubMedPubMedCentralCrossRef
168.
Modler AJ, Gast K, Lutsch G, Damaschun G. Assembly of amyloid protofibrils via critical oligomers–a novel pathway of amyloid formation. J Mol Biol. 2003;325:135–48.PubMedCrossRef
169.
Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci Publ Protein Soc. 2000;9:1960–7.CrossRef
170.
Plakoutsi G, Bemporad F, Calamai M, Taddei N, Dobson CM, Chiti F. Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates. J Mol Biol. 2005;351:910–22.PubMedCrossRef
171.
Matsumura S, Shinoda K, Yamada M, Yokojima S, Inoue M, Ohnishi T, et al. Two distinct amyloid β-protein (aβ) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J Biol Chem. 2011;286:11555–62.PubMedPubMedCentralCrossRef
172.
Fu Z, Aucoin D, Davis J, Van Nostrand WE, Smith SO. Mechanism of nucleated conformational conversion of Aβ42. Biochemistry. 2015;54:4197–207.PubMedCrossRef
173.
Lasagna-Reeves CA, Glabe CG, Kayed R. Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem. 2011;286:22122–30.PubMedPubMedCentralCrossRef
174.
Michaels TCT, Šarić A, Curk S, Bernfur K, Arosio P, Meisl G, et al. Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Aβ42 peptide. Nat Chem. 2020;12:445–51.PubMedCrossRef
175.
Cohen SIA, Vendruscolo M, Dobson CM, Knowles TPJ. From macroscopic measurements to microscopic mechanisms of protein aggregation. J Mol Biol. 2012;421:160–71.PubMedCrossRef
176.
Lee VM-Y. Amyloid binding ligands as Alzheimer’s disease therapies. Neurobiol Aging. 2002;23:1039–42.
177.
178.
179.
Staats R, Michaels TCT, Flagmeier P, Chia S, Horne RI, Habchi J, et al. Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter. Commun Chem. 2020;3:1–9.CrossRef
180.
Knowles TPJ, Waudby CA, Devlin GL, Cohen SIA, Aguzzi A, Vendruscolo M, et al. An Analytical solution to the kinetics of breakable filament assembly. Science. 2009;326:1533–7.ADSPubMedCrossRef
181.
Meisl G, Kirkegaard JB, Arosio P, Michaels TCT, Vendruscolo M, Dobson CM, et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat Protoc. 2016;11:252–72.PubMedCrossRef
182.
Cohen SIA, Vendruscolo M, Welland ME, Dobson CM, Terentjev EM, Knowles TPJ. Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. J Chem Phys. 2011;135:065105.
183.
Cohen SIA, Vendruscolo M, Dobson CM, Knowles TPJ. Nucleated polymerization with secondary pathways II. Determination of self-consistent solutions to growth processes described by non-linear master equations. J Chem Phys. 2011;135:065106.
184.
Cohen SIA, Vendruscolo M, Dobson CM, Knowles TPJ. Nucleated polymerization with secondary pathways III. Equilibrium behavior and oligomer populations. J Chem Phys. 2011;135:065107.
185.
Meisl G, Rajah L, I. Cohen SA, Pfammatter M, Šarić A, Hellstrand E, et al. Scaling behaviour and rate-determining steps in filamentous self-assembly. Chem Sci. 2017;8:7087–97.
186.
187.
188.
Young LJ, Schierle GSK, Kaminski CF. Imaging Aβ(1–42) fibril elongation reveals strongly polarised growth and growth incompetent states. Phys Chem Chem Phys. 2017;19:27987–96.PubMedPubMedCentralCrossRef
189.
Habchi J, Chia S, Galvagnion C, Michaels TCT, Bellaiche MMJ, Ruggeri FS, et al. Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. Nat Chem. 2018;10:673–83.PubMedCrossRef
190.
Galvagnion C, Buell AK, Meisl G, Michaels TCT, Vendruscolo M, Knowles TPJ, et al. Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol. 2015;11:229–34.PubMedPubMedCentralCrossRef
191.
Knowles TPJ, White DA, Abate AR, Agresti JJ, Cohen SIA, Sperling RA, et al. Observation of spatial propagation of amyloid assembly from single nuclei. Proc Natl Acad Sci USA. 2011;108:14746–51.ADSPubMedPubMedCentralCrossRef
192.
Törnquist M, T. Michaels TC, Sanagavarapu K, Yang X, Meisl G, A. Cohen SI, et al. Secondary nucleation in amyloid formation. Chem Commun. 2018;54:8667–84.
193.
194.
Ferrone FA, Hofrichter J, Eaton WA. Kinetics of sickle hemoglobin polymerization: II. A double nucleation mechanism. J Mol Biol. 1985;183:611–31.
195.
196.
Foderà V, Librizzi F, Groenning M, van de Weert M, Leone M. Secondary nucleation and accessible surface in insulin amyloid fibril formation. J Phys Chem B. 2008;112:3853–8.PubMedCrossRef
197.
198.
Thacker D, Barghouth M, Bless M, Zhang E, Linse S. Direct observation of secondary nucleation along the fibril surface of the amyloid β 42 peptide. Proc Natl Acad Sci USA. 2023;120: e2220664120.PubMedPubMedCentralCrossRef
199.
Zimmermann MR, Bera SC, Meisl G, Dasadhikari S, Ghosh S, Linse S, et al. Mechanism of secondary nucleation at the single fibril level from direct observations of Aβ42 aggregation. J Am Chem Soc. 2021;143:16621–9.PubMedCrossRef
200.
Jan A, Adolfsson O, Allaman I, Buccarello A-L, Magistretti PJ, Pfeifer A, et al. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem. 2011;286:8585–96.PubMedCrossRef
201.
Hill EK, Krebs B, Goodall DG, Howlett GJ, Dunstan DE. Shear flow induces amyloid fibril formation. Biomacromol. 2006;7:10–3.CrossRef
202.
Xue W-F, Homans SW, Radford SE. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci USA. 2008;105:8926–31.ADSPubMedPubMedCentralCrossRef
203.
Bett C, Joshi-Barr S, Lucero M, Trejo M, Liberski P, Kelly JW, et al. Biochemical properties of highly neuroinvasive prion strains. PLOS Pathog. 2012;8: e1002522.PubMedPubMedCentralCrossRef
204.
Kundel F, Hong L, Falcon B, McEwan WA, Michaels TCT, Meisl G, et al. Measurement of tau filament fragmentation provides insights into prion-like spreading. ACS Chem Neurosci. 2018;9:1276–82.PubMedCrossRef
205.
Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating sup35 prion conformers. Science. 2004;304:1793–7.ADSPubMedCrossRef
206.
Kraus A, Saijo E, Metrick MA, Newell K, Sigurdson CJ, Zanusso G, et al. Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol (Berl). 2019;137:585–98.PubMedCrossRef
207.
208.
Xue W-F, Hellewell AL, Gosal WS, Homans SW, Hewitt EW, Radford SE. Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem. 2009;284:34272–82.PubMedPubMedCentralCrossRef
209.
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA. 2009;106:4012–7.ADSPubMedPubMedCentralCrossRef
210.
Zhang X, Wesén E, Kumar R, Bernson D, Gallud A, Paul A, et al. Correlation between cellular uptake and cytotoxicity of fragmented α-synuclein amyloid fibrils suggests intracellular basis for toxicity. ACS Chem Neurosci. 2020;11:233–41.PubMedCrossRef
211.
Bett C, Lawrence J, Kurt TD, Orru C, Aguilar-Calvo P, Kincaid AE, et al. Enhanced neuroinvasion by smaller, soluble prions. Acta Neuropathol Commun. 2017;5:32.PubMedPubMedCentralCrossRef
212.
Michaels TCT, Lazell HW, Arosio P, Knowles TPJ. Dynamics of protein aggregation and oligomer formation governed by secondary nucleation. J Chem Phys. 2015;143: 054901.ADSPubMedCrossRef
213.
Yang J, Dear AJ, Michaels TCT, Dobson CM, Knowles TPJ, Wu S, et al. Direct observation of oligomerization by single molecule fluorescence reveals a multistep aggregation mechanism for the yeast prion protein Ure2. J Am Chem Soc. 2018;140:2493–503.PubMedPubMedCentralCrossRef
214.
Iljina M, Garcia GA, Horrocks MH, Tosatto L, Choi ML, Ganzinger KA, et al. Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proc Natl Acad Sci USA. 2016;113:E1206–15.PubMedPubMedCentralCrossRef
215.
Babinchak WM, Surewicz WK. Liquid–liquid phase separation and its mechanistic role in pathological protein aggregation. J Mol Biol. 2020;432:1910–25.PubMedPubMedCentralCrossRef
216.
Alberti S, Gladfelter A, Mittag T. Considerations and challenges in studying liquid-liquid phase separation and biomolecular condensates. Cell. 2019;176:419–34.PubMedPubMedCentralCrossRef
217.
218.
Mitrea DM, Mittasch M, Gomes BF, Klein IA, Murcko MA. Modulating biomolecular condensates: a novel approach to drug discovery. Nat Rev Drug Discov. 2022;21:841–62.PubMedPubMedCentralCrossRef
219.
220.
Farahi N, Lazar T, Wodak SJ, Tompa P, Pancsa R. Integration of data from liquid–liquid phase separation databases highlights concentration and dosage sensitivity of LLPS drivers. Int J Mol Sci. 2021;22:3017.PubMedPubMedCentralCrossRef
221.
Krainer G, Welsh TJ, Joseph JA, Espinosa JR, Wittmann S, de Csilléry E, et al. Reentrant liquid condensate phase of proteins is stabilized by hydrophobic and non-ionic interactions. Nat Commun. 2021;12:1085.ADSPubMedPubMedCentralCrossRef
222.
Martin EW, Mittag T. Relationship of sequence and phase separation in protein low-complexity regions. Biochemistry. 2018;57:2478–87.PubMedCrossRef
223.
Vendruscolo M, Fuxreiter M. Towards sequence-based principles for protein phase separation predictions. Curr Opin Chem Biol. 2023;75: 102317.PubMedCrossRef
224.
Alberti S, Halfmann R, King O, Kapila A, Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell. 2009;137:146–58.PubMedPubMedCentralCrossRef
225.
Franzmann TM, Alberti S. Prion-like low-complexity sequences: Key regulators of protein solubility and phase behavior. J Biol Chem. 2019;294:7128–36.PubMedCrossRef
226.
Vendruscolo M, Fuxreiter M. Sequence determinants of the aggregation of proteins within condensates generated by liquid-liquid phase separation. J Mol Biol. 2022;434: 167201.PubMedCrossRef
227.
228.
Das RK, Pappu RV. Conformations of intrinsically disordered proteins are influenced by linear sequence distributions of oppositely charged residues. Proc Natl Acad Sci USA. 2013;110:13392–7.ADSPubMedPubMedCentralCrossRef
229.
Cascella R, Bigi A, Riffert DG, Gagliani MC, Ermini E, Moretti M, et al. A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. Sci Adv. 2022;8:eabm6376.
230.
Chen Y, Cohen TJ. Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 2019;294:3696–706.PubMedPubMedCentralCrossRef
231.
Hans F, Glasebach H, Kahle PJ. Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. J Biol Chem. 2020;295:673–89.PubMedCrossRef
232.
Hardenberg M, Horvath A, Ambrus V, Fuxreiter M, Vendruscolo M. Widespread occurrence of the droplet state of proteins in the human proteome. Proc Natl Acad Sci USA. 2020;117:33254–62.ADSPubMedPubMedCentralCrossRef
233.
French RL, Grese ZR, Aligireddy H, Dhavale DD, Reeb AN, Kedia N, et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem. 2019;294:6696–709.PubMedPubMedCentralCrossRef
234.
Kumar R, Das S, Mohite GM, Rout SK, Halder S, Jha NN, et al. Cytotoxic oligomers and fibrils trapped in a gel-like state of α-synuclein assemblies. Angew Chem Int Ed. 2018;57:5262–6.CrossRef
235.
Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska KM, Bennett RE, Dujardin S, et al. Tau protein liquid–liquid phase separation can initiate tau aggregation. EMBO J. 2018;37: e98049.PubMedPubMedCentralCrossRef
236.
237.
Ash PEA, Lei S, Shattuck J, Boudeau S, Carlomagno Y, Medalla M, et al. TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc Natl Acad Sci USA. 2021;118: e2014188118.PubMedPubMedCentralCrossRef
238.
Xing Y, Nandakumar A, Kakinen A, Sun Y, Davis TP, Ke PC, et al. Amyloid Aggregation under the Lens of Liquid-Liquid Phase Separation. J Phys Chem Lett. 2021;12:368–78.PubMedCrossRef
239.
Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274:25945–52.
240.
Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010;6:140–7.PubMedCrossRef
241.
Mannini B, Habchi J, Chia S, Ruggeri FS, Perni M, Knowles TPJ, et al. Stabilization and characterization of cytotoxic Aβ40 oligomers isolated from an aggregation reaction in the presence of zinc ions. ACS Chem Neurosci. 2018;9:2959–71.PubMedCrossRef
242.
Lassen LB, Gregersen E, Isager AK, Betzer C, Kofoed RH, Jensen PH. ELISA method to detect α-synuclein oligomers in cell and animal models. PLoS ONE. 2018;13: e0196056.PubMedPubMedCentralCrossRef
243.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer’s disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417–22.ADSPubMedPubMedCentralCrossRef
244.
Brännström K, Lindhagen-Persson M, Gharibyan AL, Iakovleva I, Vestling M, Sellin ME, et al. A generic method for design of oligomer-specific antibodies. PLoS ONE. 2014;9: e90857.ADSPubMedPubMedCentralCrossRef
245.
Liu L, Kwak H, Lawton TL, Jin S-X, Meunier AL, Dang Y, et al. An ultra-sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma. Alzheimers Dement. 2022;18:1186–202.PubMedCrossRef
246.
Aprile FA, Sormanni P, Podpolny M, Chhangur S, Needham L-M, Ruggeri FS, et al. Rational design of a conformation-specific antibody for the quantification of Aβ oligomers. Proc Natl Acad Sci USA. 2020;117(24):13509–18.ADSPubMedPubMedCentralCrossRef
247.
Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener. 2016;11:7.PubMedPubMedCentralCrossRef
248.
Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis. 2020;146: 105086.PubMedCrossRef
249.
Chatterjee T, Knappik A, Sandford E, Tewari M, Choi SW, Strong WB, et al. Direct kinetic fingerprinting and digital counting of single protein molecules. Proc Natl Acad Sci USA. 2020;117:22815–22.ADSPubMedPubMedCentralCrossRef
250.
Kool J, Jonker N, Irth H, Niessen WMA. Studying protein–protein affinity and immobilized ligand–protein affinity interactions using MS-based methods. Anal Bioanal Chem. 2011;401:1109.PubMedPubMedCentralCrossRef
251.
Borch J, Jørgensen TJ, Roepstorff P. Mass spectrometric analysis of protein interactions. Curr Opin Chem Biol. 2005;9:509–16.PubMedCrossRef
252.
Buijs J, Franklin GC. SPR-MS in functional proteomics. Brief Funct Genomic Proteomic. 2005;4:39–47.PubMedCrossRef
253.
Zhang G, Ueberheide BM, Waldemarson S, Myung S, Molloy K, Eriksson J, et al. Protein quantitation using mass spectrometry. Methods Mol Biol. 2010;673:211–22.PubMedPubMedCentralCrossRef
254.
Heck AJR. Native mass spectrometry: a bridge between interactomics and structural biology. Nat Methods. 2008;5:927–33.PubMedCrossRef
255.
Mannini B, Mulvihill E, Sgromo C, Cascella R, Khodarahmi R, Ramazzotti M, et al. Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity. ACS Chem Biol. 2014;9:2309–17.PubMedCrossRef
256.
Horrocks MH, Tosatto L, Dear AJ, Garcia GA, Iljina M, Cremades N, et al. Fast flow microfluidics and single-molecule fluorescence for the rapid characterization of α-synuclein oligomers. Anal Chem. 2015;87:8818–26.PubMedCrossRef
257.
Limbocker R, Chia S, Ruggeri FS, Perni M, Cascella R, Heller GT, et al. Trodusquemine enhances Aβ 42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nat Commun. 2019;10:225.ADSPubMedPubMedCentralCrossRef
258.
Limbocker R, Mannini B, Ruggeri FS, Cascella R, Xu CK, Perni M, et al. Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Commun Biol. 2020;3:1–10.CrossRef
259.
Modler AJ, Fabian H, Sokolowski F, Lutsch G, Gast K, Damaschun G. Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation. Amyloid. 2004;11:215–31.PubMedCrossRef
260.
Upadhaya AR, Lungrin I, Yamaguchi H, Fändrich M, Thal DR. High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. J Cell Mol Med. 2012;16:287–95.PubMedPubMedCentralCrossRef
261.
Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem. 2001;276:35176–84.PubMedCrossRef
262.
Ruggeri FS, Šneideris T, Vendruscolo M, Knowles TPJ. Atomic force microscopy for single molecule characterisation of protein aggregation. Arch Biochem Biophys. 2019;664:134–48.PubMedPubMedCentralCrossRef
263.
Vivoli Vega M, Cascella R, Chen SW, Fusco G, De Simone A, Dobson CM, et al. The toxicity of misfolded protein oligomers is independent of their secondary structure. ACS Chem Biol. 2019;14:1593–600.PubMedCrossRef
264.
Capitini C, Patel JR, Natalello A, D’Andrea C, Relini A, Jarvis JA, et al. Structural differences between toxic and nontoxic HypF-N oligomers. Chem Commun. 2018;54:8637–40.CrossRef
265.
Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, et al. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem. 2010;285:6071–9.PubMedCrossRef
266.
267.
Williams AD, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, et al. Structural properties of Abeta protofibrils stabilized by a small molecule. Proc Natl Acad Sci USA. 2005;102:7115–20.ADSPubMedPubMedCentralCrossRef
268.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13:80.PubMedPubMedCentralCrossRef
269.
Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575–88.PubMedCrossRef
270.
Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13:98.PubMedPubMedCentralCrossRef
271.
Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8:398–410.PubMedPubMedCentral
272.
273.
Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, Aducanumab, and Gantenerumab — binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s Disease. Neurotherapeutics. 2023;20:195–206.
274.
Tatini F, Pugliese AM, Traini C, Niccoli S, Maraula G, Ed Dami T, et al. Amyloid-β oligomer synaptotoxicity is mimicked by oligomers of the model protein HypF-N. Neurobiol Aging. 2013;34:2100–9.
275.
Baerends E, Soud K, Folke J, Pedersen A-K, Henmar S, Konrad L, et al. Modeling the early stages of Alzheimer’s disease by administering intracerebroventricular injections of human native Aβ oligomers to rats. Acta Neuropathol Commun. 2022;10:113.PubMedPubMedCentralCrossRef
276.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853–62.PubMedPubMedCentralCrossRef
277.
Kitazawa M, Medeiros R, LaFerla FM. Transgenic mouse models of alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des. 2012;18:1131–47.PubMedPubMedCentralCrossRef
278.
Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The “Arctic” APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887–93.PubMedCrossRef
279.
280.
281.
Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35:352–8.PubMedPubMedCentralCrossRef
282.
Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73:104–19.PubMedCrossRef
283.
McDonald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain J Neurol. 2010;133:1328–41.CrossRef
284.
285.
Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, et al. Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010;277:3051–67.PubMedPubMedCentralCrossRef
286.
287.
Georganopoulou DG, Chang L, Nam J-M, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci USA. 2005;102:2273–6.ADSPubMedPubMedCentralCrossRef
288.
Park MJ, Cheon S-M, Bae H-R, Kim S-H, Kim JW. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol. 2011;7:215–22.PubMedPubMedCentralCrossRef
289.
Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab S a. S, Kasai T, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75:1766–72.
290.
Sideris DI, Danial JSH, Emin D, Ruggeri FS, Xia Z, Zhang YP, et al. Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer’s disease. Brain Commun. 2021;3:fcab147.
291.
Hong W, Wang Z, Liu W, O’Malley TT, Jin M, Willem M, et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain. Acta Neuropathol (Berl). 2018;136:19–40.PubMedCrossRef
292.
De S, Whiten DR, Ruggeri FS, Hughes C, Rodrigues M, Sideris DI, et al. Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression. Acta Neuropathol Commun. 2019;7:120.PubMedPubMedCentralCrossRef
293.
Ochiishi T, Kaku M, Kiyosue K, Doi M, Urabe T, Hattori N, et al. New Alzheimer’s disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid β oligomers. Sci Rep. 2019;9:17368.ADSPubMedPubMedCentralCrossRef
294.
Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, et al. A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845–56.PubMedPubMedCentralCrossRef
295.
Kass B, Schemmert S, Zafiu C, Pils M, Bannach O, Kutzsche J, et al. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep Med. 2022;3: 100630.PubMedPubMedCentralCrossRef
296.
Kiechle M, von Einem B, Höfs L, Voehringer P, Grozdanov V, Markx D, et al. In vivo protein complementation demonstrates presynaptic α-synuclein oligomerization and age-dependent accumulation of 8–16-mer oligomer species. Cell Rep. 2019;29:2862–2874.e9.PubMedCrossRef
297.
Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, et al. Distinct region-specific α-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci. 2010;30:3409–18.PubMedPubMedCentralCrossRef
298.
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507–11.ADSPubMedCrossRef
299.
Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79–84.PubMedCrossRef
300.
Zampagni M, Cascella R, Casamenti F, Grossi C, Evangelisti E, Wright D, et al. A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J Cell Mol Med. 2011;15:2106–16.PubMedPubMedCentralCrossRef
301.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.ADSPubMedCrossRef
302.
Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, et al. Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener. 2017;12:27.PubMedPubMedCentralCrossRef
303.
Cline EN, Das A, Bicca MA, Mohammad SN, Schachner LF, Kamel JM, et al. A novel crosslinking protocol stabilizes amyloid β oligomers capable of inducing Alzheimer’s-associated pathologies. J Neurochem. 2019;148:822–36.PubMedPubMedCentralCrossRef
304.
Froula JM, Castellana-Cruz M, Anabtawi NM, Camino JD, Chen SW, Thrasher DR, et al. Defining α-synuclein species responsible for Parkinson’s disease phenotypes in mice. J Biol Chem. 2019;294:10392–406.PubMedPubMedCentralCrossRef
305.
Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxid Med Cell Longev. 2019;2019: e2105607.CrossRef
306.
Evangelisti E, Cascella R, Becatti M, Marrazza G, Dobson CM, Chiti F, et al. Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. Sci Rep. 2016;6:32721.ADSPubMedPubMedCentralCrossRef
307.
308.
Mannini B, Cascella R, Zampagni M, van Waarde-Verhagen M, Meehan S, Roodveldt C, et al. Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proc Natl Acad Sci USA. 2012;109:12479–84.ADSPubMedPubMedCentralCrossRef
309.
310.
Ladiwala ARA, Litt J, Kane RS, Aucoin DS, Smith SO, Ranjan S, et al. Conformational Differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem. 2012;287:24765–73.PubMedPubMedCentralCrossRef
311.
Krishnan R, Goodman JL, Mukhopadhyay S, Pacheco CD, Lemke EA, Deniz AA, et al. Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proc Natl Acad Sci USA. 2012;109:11172–7.ADSPubMedPubMedCentralCrossRef
312.
Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci. 2017;37:152–63.PubMedPubMedCentralCrossRef
313.
De S, Wirthensohn DC, Flagmeier P, Hughes C, Aprile FA, Ruggeri FS, et al. Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms. Nat Commun. 2019;10:1541.ADSPubMedPubMedCentralCrossRef
314.
Evangelisti E, Cecchi C, Cascella R, Sgromo C, Becatti M, Dobson CM, et al. Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers. J Cell Sci. 2012;125(10):2416–2427.
315.
Rushworth JV, Griffiths HH, Watt NT, Hooper NM. Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem. 2013;288:8935–51.PubMedPubMedCentralCrossRef
316.
Wang HY, Lee DH, D’Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem. 2000;275:5626–32.
317.
Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P. Cellular receptors of amyloid β oligomers (AβOs) in Alzheimer’s disease. Int J Mol Sci. 2018;19:1884.PubMedPubMedCentralCrossRef
318.
Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-β neurotoxicity. J Biol Chem. 2013;288:654–65.PubMedCrossRef
319.
320.
321.
Fani G, Mannini B, Vecchi G, Cascella R, Cecchi C, Dobson CM, et al. Aβ oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors. ACS Chem Neurosci. 2021;12:766–81.PubMedCrossRef
322.
323.
Friedrich RP, Tepper K, Rönicke R, Soom M, Westermann M, Reymann K, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci USA. 2010;107:1942–7.ADSPubMedPubMedCentralCrossRef
324.
Serra-Batiste M, Ninot-Pedrosa M, Bayoumi M, Gairí M, Maglia G, Carulla N. Aβ42 assembles into specific β-barrel pore-forming oligomers in membrane-mimicking environments. Proc Natl Acad Sci USA. 2016;113:10866–71.ADSPubMedPubMedCentralCrossRef
325.
Wesén E, Jeffries GDM, Matson Dzebo M, Esbjörner EK. Endocytic uptake of monomeric amyloid-β peptides is clathrin- and dynamin-independent and results in selective accumulation of Aβ(1–42) compared to Aβ(1–40). Sci Rep. 2017;7:2021.ADSPubMedPubMedCentralCrossRef
326.
Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM. Amyloid-β receptors: the good, the bad, and the prion protein. J Biol Chem. 2016;291:3174–83.PubMedCrossRef
327.
Miller EC, Teravskis PJ, Dummer BW, Zhao X, Huganir RL, Liao D. Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits. Eur J Neurosci. 2014;39:1214–24.PubMedPubMedCentralCrossRef
328.
Shin WS, Di J, Cao Q, Li B, Seidler PM, Murray KA, et al. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alzheimers Res Ther. 2019;11:86.PubMedPubMedCentralCrossRef
329.
Chia S, Flagmeier P, Habchi J, Lattanzi V, Linse S, Dobson CM, et al. Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates. Proc Natl Acad Sci USA. 2017;114(30):8005–10.
330.
Hallacli E, Kayatekin C, Nazeen S, Wang XH, Sheinkopf Z, Sathyakumar S, et al. The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell. 2022;185:2035–2056.e33.PubMedPubMedCentralCrossRef
331.
Bucciantini M, Rigacci S, Berti A, Pieri L, Cecchi C, Nosi D, et al. Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar aggregates. FASEB J. 2005;19:437–9.PubMedCrossRef
332.
Perni M, Galvagnion C, Maltsev A, Meisl G, Müller MBD, Challa PK, et al. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci USA. 2017;114:E1009–17.PubMedPubMedCentralCrossRef
333.
Errico S, Ramshini H, Capitini C, Canale C, Spaziano M, Barbut D, et al. Quantitative measurement of the affinity of toxic and nontoxic misfolded protein oligomers for lipid bilayers and of its modulation by lipid composition and trodusquemine. ACS Chem Neurosci. 2021;12:3189–202.PubMedCrossRef
334.
Nguyen PT, Zottig X, Sebastiao M, Arnold AA, Marcotte I, Bourgault S. Identification of transmissible proteotoxic oligomer-like fibrils that expand conformational diversity of amyloid assemblies. Commun Biol. 2021;4:1–14.CrossRef
335.
Fani G, La Torre CE, Cascella R, Cecchi C, Vendruscolo M, Chiti F. Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species. Cell Mol Life Sci. 2022;79:500.PubMedPubMedCentralCrossRef
336.
Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280:17294–300.PubMedCrossRef
337.
Limbocker R, Mannini B, Cataldi R, Chhangur S, Wright AK, Kreiser RP, et al. Rationally designed antibodies as research tools to study the structure–toxicity relationship of amyloid-β oligomers. Int J Mol Sci. 2020;21:4542.
338.
339.
Patten DA, Germain M, Kelly MA, Slack RS. Reactive oxygen species: stuck in the middle of neurodegeneration. J Alzheimers Dis. 2010;20(Suppl 2):S357–367.PubMedCrossRef
340.
Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K, et al. Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 2005;12:19–24.PubMedCrossRef
341.
342.
Hou X, Parkington HC, Coleman HA, Mechler A, Martin LL, Aguilar M-I, et al. Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J Neurochem. 2007;100:446–57.PubMedCrossRef
343.
Sartiani L, Bucciantini M, Spinelli V, Leri M, Natalello A, Nosi D, et al. Biochemical and electrophysiological modification of amyloid transthyretin on cardiomyocytes. Biophys J. 2016;111:2024–38.PubMedPubMedCentralCrossRef
344.
Nakano T, Onoue K, Terada C, Terasaki S, Ishihara S, Hashimoto Y, et al. Transthyretin amyloid cardiomyopathy: impact of transthyretin amyloid deposition in myocardium on cardiac morphology and function. J Pers Med. 2022;12:792.PubMedPubMedCentralCrossRef
345.
346.
Guglielmotto M, Monteleone D, Piras A, Valsecchi V, Tropiano M, Ariano S, et al. Aβ1-42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy. 2014;10:1827–43.PubMedPubMedCentralCrossRef
347.
Söllvander S, Nikitidou E, Brolin R, Söderberg L, Sehlin D, Lannfelt L, et al. Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol Neurodegener. 2016;11:38.PubMedPubMedCentralCrossRef
348.
Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer’s disease. Neurobiol Aging. 2012;33:1329–42.PubMedCrossRef
349.
Richter M, Vidovic N, Biber K, Dolga A, Culmsee C, Dodel R. The neuroprotective role of microglial cells against amyloid beta-mediated toxicity in organotypic hippocampal slice cultures. Brain Pathol Zurich Switz. 2020;30:589–602.CrossRef
350.
Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306–18.PubMedCrossRef
351.
Waudby CA, Knowles TPJ, Devlin GL, Skepper JN, Ecroyd H, Carver JA, et al. The interaction of αb-crystallin with mature α-synuclein amyloid fibrils inhibits their elongation. Biophys J. 2010;98:843–51.PubMedPubMedCentralCrossRef
352.
Shammas SL, Waudby CA, Wang S, Buell AK, Knowles TPJ, Ecroyd H, et al. Binding of the molecular chaperone αB-Crystallin to Aβ amyloid fibrils inhibits fibril elongation. Biophys J. 2011;101:1681–9.PubMedPubMedCentralCrossRef
353.
Kundel F, De S, Flagmeier P, Horrocks MH, Kjaergaard M, Shammas SL, et al. Hsp70 inhibits the nucleation and elongation of tau and sequesters tau aggregates with high affinity. ACS Chem Biol. 2018;13:636–46.PubMedPubMedCentralCrossRef
354.
Cohen SIA, Arosio P, Presto J, Kurudenkandy FR, Biverstål H, Dolfe L, et al. A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol. 2015;22:207–13.PubMedPubMedCentralCrossRef
355.
Kiuchi Y, Isobe Y, Fukushima K. Entactin-induced inhibition of human amyloid β-protein fibril formation in vitro. Neurosci Lett. 2001;305:119–22.PubMedCrossRef
356.
Dandanell Agerschou E, Borgmann V, M. Wördehoff M, Hoyer W. Inhibitor and substrate cooperate to inhibit amyloid fibril elongation of α-synuclein. Chem Sci. 2020;11:11331–7.
357.
Doytchinova I, Atanasova M, Salamanova E, Ivanov S, Dimitrov I. Curcumin inhibits the primary nucleation of amyloid-beta peptide: a molecular dynamics study. Biomolecules. 2020;10:1323.PubMedPubMedCentralCrossRef
358.
Du W-J, Guo J-J, Gao M-T, Hu S-Q, Dong X-Y, Han Y-F, et al. Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Sci Rep. 2015;5:7992.PubMedPubMedCentralCrossRef
359.
Nagaraj M, Najarzadeh Z, Pansieri J, Biverstål H, Musteikyte G, Smirnovas V, et al. Chaperones mainly suppress primary nucleation during formation of functional amyloid required for bacterial biofilm formation. Chem Sci. 2022;13:536–53.PubMedCrossRef
360.
Ghadami SA, Chia S, Ruggeri FS, Meisl G, Bemporad F, Habchi J, et al. Transthyretin inhibits primary and secondary nucleations of amyloid-β peptide aggregation and reduces the toxicity of its oligomers. Biomacromolecules. 2020;21:1112–25.
361.
Meade RM, Morris KJ, Watt KJC, Williams RJ, Mason JM. The library derived 4554w peptide inhibits primary nucleation of α-synuclein. J Mol Biol. 2020;432: 166706.PubMedCrossRef
362.
Perni M, Flagmeier P, Limbocker R, Cascella R, Aprile FA, Galvagnion C, et al. Multistep inhibition of α-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem Biol. 2018;13:2308–19.PubMedCrossRef
363.
364.
Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, Perni M, et al. Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease. Proc Natl Acad Sci USA. 2017;114:E200–8.PubMedCrossRef
365.
Aprile FA, Sormanni P, Perni M, Arosio P, Linse S, Knowles TPJ, et al. Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method. Sci Adv. 2017;3: e1700488.ADSPubMedPubMedCentralCrossRef
366.
Limbocker R, Errico S, Barbut D, Knowles TPJ, Vendruscolo M, Chiti F, et al. Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic. Nat Prod Rep. 2022;39:742–53.PubMedCrossRef
367.
368.
369.
Linse S, Sormanni P, O’Connell DJ. An aggregation inhibitor specific to oligomeric intermediates of Aβ42 derived from phage display libraries of stable, small proteins. Proc Natl Acad Sci USA. 2022;119: e2121966119.PubMedPubMedCentralCrossRef
370.
Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15:558–66.PubMedCrossRef
371.
Ladiwala ARA, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid aβ into off-pathway conformers. J Biol Chem. 2010;285:24228–37.PubMedPubMedCentralCrossRef
372.
Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol. 2010;20:54–62.PubMedPubMedCentralCrossRef
373.
Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629–34.ADSPubMedPubMedCentralCrossRef
374.
Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92.
375.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16.PubMedCrossRef
376.
Yan NL, Santos-Martins D, Nair R, Chu A, Wilson IA, Johnson KA, et al. Discovery of potent coumarin-based kinetic stabilizers of amyloidogenic immunoglobulin light chains using structure-based design. J Med Chem. 2021;64:6273–99.PubMedPubMedCentralCrossRef
377.
Chiti F, Kelly JW. Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation. Curr Opin Struct Biol. 2022;72:267–78.PubMedCrossRef
378.
Heller GT, Aprile FA, Michaels TCT, Limbocker R, Perni M, Ruggeri FS, et al. Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease. Sci Adv. 6:eabb5924.
379.
Löhr T, Kohlhoff K, Heller GT, Camilloni C, Vendruscolo M. A small molecule stabilizes the disordered native state of the Alzheimer’s Aβ Peptide. ACS Chem Neurosci. 2022;13:1738–45.PubMedCrossRef
380.
Heller GT, Sormanni P, Vendruscolo M. Targeting disordered proteins with small molecules using entropy. Trends Biochem Sci. 2015;40:491–6.PubMedCrossRef
381.
Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6.PubMedPubMedCentralCrossRef
382.
Selkoe D. β-secretase inhibitors for Alzheimer’s disease: heading in the wrong direction? Lancet Neurol. 2019;18:624–6.PubMedCrossRef
383.
384.
Chiozzi P, Sarti AC, Sanz JM, Giuliani AL, Adinolfi E, Vultaggio-Poma V, et al. Amyloid β-dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine. Sci Rep. 2019;9:6475.ADSPubMedPubMedCentralCrossRef
385.
Cao Q, Shin WS, Chan H, Vuong CK, Dubois B, Li B, et al. Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nat Chem. 2018;10:1213–21.PubMedPubMedCentralCrossRef
386.
Foley AR, Roseman GP, Chan K, Smart A, Finn TS, Yang K, et al. Evidence for aggregation-independent, PrPC-mediated Aβ cellular internalization. Proc Natl Acad Sci USA. 2020;117:28625–31.ADSPubMedPubMedCentralCrossRef
387.
Cappelli S, Penco A, Mannini B, Cascella R, Wilson MR, Ecroyd H, et al. Effect of molecular chaperones on aberrant protein oligomers in vitro: super-versus sub-stoichiometric chaperone concentrations. Biol Chem. 2016;397:401–15.PubMedCrossRef
388.
Ojha J, Masilamoni G, Dunlap D, Udoff RA, Cashikar AG. Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. Mol Cell Biol. 2011;31:3146–57.PubMedPubMedCentralCrossRef
389.
Garai K, Posey AE, Li X, Buxbaum JN, Pappu RV. Inhibition of amyloid beta fibril formation by monomeric human transthyretin. Protein Sci. 2018;27:1252–61.PubMedPubMedCentralCrossRef
390.
Cascella R, Conti S, Tatini F, Evangelisti E, Scartabelli T, Casamenti F, et al. Extracellular chaperones prevent Aβ42-induced toxicity in rat brains. Biochim Biophys Acta. 2013;1832:1217–26.PubMedCrossRef
391.
Cascella R, Conti S, Mannini B, Li X, Buxbaum JN, Tiribilli B, et al. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim Biophys Acta BBA - Mol Basis Dis. 2013;1832:2302–14.CrossRef
392.
Beeg M, Stravalaci M, Romeo M, Carrá AD, Cagnotto A, Rossi A, et al. Clusterin binds to aβ1–42 oligomers with high affinity and interferes with peptide aggregation by inhibiting primary and secondary nucleation. J Biol Chem. 2016;291:6958–66.PubMedPubMedCentralCrossRef
393.
394.
Andreasen M, Lorenzen N, Otzen D. Interactions between misfolded protein oligomers and membranes: a central topic in neurodegenerative diseases? Biochim Biophys Acta. 2015;1848:1897–907.PubMedCrossRef
395.
Mrak RE, Griffin WST. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging. 2001;22:903–8.PubMedCrossRef
396.
Kempuraj D, Thangavel R, Selvakumar GP, Zaheer S, Ahmed ME, Raikwar SP, et al. Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration. Front Cell Neurosci. 2017;11:216.PubMedPubMedCentralCrossRef
397.
Batista AF, Rody T, Forny-Germano L, Cerdeiro S, Bellio M, Ferreira ST, et al. Interleukin-1β mediates alterations in mitochondrial fusion/fission proteins and memory impairment induced by amyloid-β oligomers. J Neuroinflammation. 2021;18:54.PubMedPubMedCentralCrossRef
398.
Steeland S, Gorlé N, Vandendriessche C, Balusu S, Brkic M, Van Cauwenberghe C, et al. Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease. EMBO Mol Med. 2018;10: e8300.PubMedPubMedCentralCrossRef
399.
400.
Xu B, Mo X, Chen J, Yu H, Liu Y. Myricetin inhibits α-synuclein amyloid aggregation by delaying the liquid-to-solid phase transition. ChemBioChem. 2022;23:e202200216.PubMedCrossRef
401.
Willander H, Presto J, Askarieh G, Biverstål H, Frohm B, Knight SD, et al. BRICHOS domains efficiently delay fibrillation of amyloid β-peptide. J Biol Chem. 2012;287:31608–17.PubMedPubMedCentralCrossRef
402.
Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces α-synuclein induced cytotoxicity in Parkinson’s disease cell model. BMC Neurosci. 2010;11:57.PubMedPubMedCentralCrossRef
403.
Smith SP, Shaw GS. A novel calcium-sensitive switch revealed by the structure of human S100B in the calcium-bound form. Structure. 1998;6:211–22.PubMedCrossRef
404.
Seidler PM, Murray KA, Boyer DR, Ge P, Sawaya MR, Hu CJ, et al. Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro. Nat Commun. 2022;13:5451.ADSPubMedPubMedCentralCrossRef
405.
Schofield DJ, Irving L, Calo L, Bogstedt A, Rees G, Nuccitelli A, et al. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo. Neurobiol Dis. 2019;132: 104582.PubMedCrossRef
406.
Sarkar S, C. Rubinsztein D. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst. 2008;4:895–901.
407.
Picone P, Bondi ML, Picone P, Bondi ML, Montana G, Bruno A, et al. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: Improved delivery by solid lipid nanoparticles. Free Radic Res. 2009;43:1133–45.PubMedCrossRef
408.
Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, et al. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimers Res Ther. 2015;7:35.PubMedPubMedCentralCrossRef
409.
410.
Moreira GG, Cantrelle F-X, Quezada A, Carvalho FS, Cristóvão JS, Sengupta U, et al. Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. Nat Commun. 2021;12:6292.ADSPubMedPubMedCentralCrossRef
411.
Mirecka EA, Shaykhalishahi H, Gauhar A, Akgül Ş, Lecher J, Willbold D, et al. Sequestration of a β-Hairpin for Control of α-Synuclein Aggregation. Angew Chem Int Ed. 2014;53:4227–30.CrossRef
412.
Kreiser RP, Wright AK, Sasser LR, Rinauro DJ, Gabriel JM, Hsu CM, et al. A brain-permeable aminosterol regulates cell membranes to mitigate the toxicity of diverse pore-forming agents. ACS Chem Neurosci. 2022;13:1219–31.PubMedCrossRef
413.
King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther. 2014;141:1–12.PubMedCrossRef
414.
Fukunaga K, Izumi H, Yabuki Y, Shinoda Y, Shioda N, Han F. Alzheimer’s disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels. J Pharmacol Sci. 2019;139:51–8.PubMedCrossRef
415.
Esteras N, Kundel F, Amodeo GF, Pavlov EV, Klenerman D, Abramov AY. Insoluble tau aggregates induce neuronal death through modification of membrane ion conductance, activation of voltage-gated calcium channels and NADPH oxidase. FEBS J. 2021;288:127–41.PubMedCrossRef
416.
Dieter F, Esselun C, Eckert GP. Redox active α-lipoic acid differentially improves mitochondrial dysfunction in a cellular model of alzheimer and its control cells. Int J Mol Sci. 2022;23:9186.PubMedPubMedCentralCrossRef
417.
Dedmon MM, Christodoulou J, Wilson MR, Dobson CM. Heat shock protein 70 inhibits α-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem. 2005;280:14733–40.PubMedCrossRef
418.
419.
Crespi GAN, Hermans SJ, Parker MW, Miles LA. Molecular basis for mid-region amyloid-β capture by leading Alzheimer’s disease immunotherapies. Sci Rep. 2015;5:9649.ADSPubMedPubMedCentralCrossRef
420.
421.
Cai X, Zhang K, Xie X, Zhu X, Feng J, Jin Z, et al. Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline. Biomaterials. 2020;231: 119678.PubMedCrossRef
422.
Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495–505.PubMedCrossRef
423.
Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting bace1 inhibits amyloid-β production in vivo. Sci Transl Med. 2011;3:84ra43–84ra43.
424.
Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8:6412.ADSPubMedPubMedCentralCrossRef
425.
Arai T, Sasaki D, Araya T, Sato T, Sohma Y, Kanai M. A cyclic KLVFF-derived peptide aggregation inhibitor induces the formation of less-toxic off-pathway amyloid-β oligomers. ChemBioChem. 2014;15:2577–83.PubMedCrossRef
426.
Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: The case for isradipine. Biochim Biophys Acta BBA - Mol Basis Dis. 2011;1812:1584–90.CrossRef
427.
Agerschou ED, Flagmeier P, Saridaki T, Galvagnion C, Komnig D, Heid L, et al. An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils. eLife. 2019;8:e46112.
428.
429.
Collier MP, Alderson TR, de Villiers CP, Nicholls D, Gastall HY, Allison TM, et al. HspB1 phosphorylation regulates its intramolecular dynamics and mechanosensitive molecular chaperone interaction with filamin C. Sci Adv. 2019;5:eaav8421.
430.
Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2023;32:89–94.PubMedCrossRef
431.
Metadata
Title
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases
Authors
Dillon J. Rinauro
Fabrizio Chiti
Michele Vendruscolo
Ryan Limbocker
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2024
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/s13024-023-00651-2

Other articles of this Issue 1/2024

Molecular Neurodegeneration 1/2024 Go to the issue

Research article

An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders

Correction

Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model

Letter to the Editor

HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases

Research article

NMNAT2 supports vesicular glycolysis via NAD homeostasis to fuel fast axonal transport

Perspective

Unraveling the dual nature of brain CD8+ T cells in Alzheimer’s disease

Research article

Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology